ONCT-808

N/A

Report date: 2024/09/13 17:51:20

Base Information

Drug NameONCT-808
Drug Alias NameONCT-808
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsWnt signalling pathway modulators
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsLymphoma, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesOncternal Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesHo'ola Therapeutics IncOncternal Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A